Conceptio › Archive › ClinicalTrials.gov
ClinicalTrials.govpublic full text

INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC

Inhibrx Biosciences, Inc · 2024
ClinicalTrials.gov · Datasets · License: Public Domain · 2024
Open Source ↗
head-and-neck-cancerimmunotherapypembrolizumab
head and neck squamous cell carcinoma (hnscc), ox40 receptor agonist, pd-l1 positive, pembrolizumab, immunotherapy, chemotherapy-free, hnscc, head and neck cancer, keytruda, oropharyngeal cancer, hypopharyngeal cancer, laryngeal cancer
This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗
Record · ID 889030
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.